dioxiram has been researched along with thiram in 1 studies
Studies (dioxiram) | Trials (dioxiram) | Recent Studies (post-2010) (dioxiram) | Studies (thiram) | Trials (thiram) | Recent Studies (post-2010) (thiram) |
---|---|---|---|---|---|
5 | 0 | 2 | 755 | 9 | 258 |
Protein | Taxonomy | dioxiram (IC50) | thiram (IC50) |
---|---|---|---|
Janus kinase 2 (a protein tyrosine kinase) | Homo sapiens (human) | 0.223 | |
bifunctional UDP-N-acetylglucosamine pyrophosphorylase/glucosamine-1-phosphate N-acetyltransferase | Mycobacterium tuberculosis H37Rv | 89.32 | |
Gamma-butyrobetaine dioxygenase | Homo sapiens (human) | 6.85 | |
Retinal dehydrogenase 1 | Homo sapiens (human) | 0.02 | |
Aldehyde dehydrogenase, mitochondrial | Homo sapiens (human) | 0.32 | |
Fructose-1,6-bisphosphatase 1 | Homo sapiens (human) | 2.29 | |
Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 0.05 | |
Protein-lysine 6-oxidase | Homo sapiens (human) | 1.04 | |
Lysyl oxidase homolog 3 | Homo sapiens (human) | 0.11 | |
Lysyl oxidase homolog 4 | Homo sapiens (human) | 0.18 | |
Histone-lysine N-methyltransferase EHMT2 | Homo sapiens (human) | 0.55 | |
Monoglyceride lipase | Homo sapiens (human) | 0.9772 | |
Histone-lysine N-methyltransferase EHMT1 | Homo sapiens (human) | 1.1 | |
Lysyl oxidase homolog 2 | Homo sapiens (human) | 0.17 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Chen, X; Huang, YY; Li, J; Li, XK; Mao, F; Ni, SS; Ren, YL; Song, RR; Wan, J; Xu, YX; Zhang, C; Zhu, J | 1 |
1 other study(ies) available for dioxiram and thiram
Article | Year |
---|---|
Development of disulfide-derived fructose-1,6-bisphosphatase (FBPase) covalent inhibitors for the treatment of type 2 diabetes.
Topics: Animals; Blood Glucose; Cysteine; Diabetes Mellitus, Type 2; Disulfides; Enzyme Inhibitors; Fructose-Bisphosphatase; Male; Mice; Structure-Activity Relationship | 2020 |